|
Synonyms: Anktiva®: nogapendekin alfa + inbakicept-pmln | IL15 D72
nogapendekin alfa is an approved drug
Compound class:
Peptide
Comment: Inogapendekin alfa is recombinant human IL-15 with an amino acid substitution (Asn72Asp/N72D) that enhances its agonist activity at the IL-15Rβγc complex. IL-15N72D increases biological activity by 4-5-fold compared to the wild type cytokine. Inogapendekin alfa is synthesised in tandem with inbakicept to generate the clinical stage IL-15 superagonist complex ALT-803.
|
| No information available. |
Summary of Clinical Use ![]() |
| A fixed-dose combination of inogapendekin alfa and inbakicept (Anktiva®) was first approved for medical use in the United States in April 2024, to treat bladder cancer. Anktiva® is administered in combination with Bacillus Calmette-Guérin (BCG). This approval was expanded in October 2026, to include treatment of BCG-unresponsive high-grade papillary-only, non-muscle invasive bladder cancer. The EU EMA authorised use of Anktiva® in February 2026. |
External links ![]() |
|
For extended ADME data see the following: Drugs.com |